Similar articles

• Patient Notes: motion sickness.

  Setness PA, Van Beusekom M. Setness PA, et al. Postgrad Med. 2004 Oct;116(4):64. doi: 10.3810/pgm.2004.10.1605. Postgrad Med. 2004. PMID: 15510594 No abstract available.
• A comparison of cinnarizine and transdermal scopolamine for the prevention of seasickness in naval crew: a double-blind, randomized, crossover study.

  Gil A, Nachum Z, Tal D, Shupak A. Gil A, et al. Clin Neuropharmacol. 2012 Jan-Feb;35(1):37-9. doi: 10.1097/WNF.0b013e31823dc125. Clin Neuropharmacol. 2012. PMID: 22139622 Clinical Trial.
• Transdermal scopolamine in the prevention of motion sickness at sea.

  Price NM, Schmitt LG, McGuire J, Shaw JE, Trobough G. Price NM, et al. Clin Pharmacol Ther. 1981 Mar;29(3):414-9. doi: 10.1038/clpt.1981.57. Clin Pharmacol Ther. 1981. PMID: 7009021 Clinical Trial.
• Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.

  Nachum Z, Shupak A, Gordon CR. Nachum Z, et al. Clin Pharmacokinet. 2006;45(6):543-66. doi: 10.2165/00003088-200645060-00001. Clin Pharmacokinet. 2006. PMID: 16719539 Review.
• [Pharmacologic agents for preventing and treating motion sickness].

  Shashkov VS, Sabaev VV. Shashkov VS, et al. Kosm Biol Aviakosm Med. 1981 Jan-Feb;15(1):9-18. Kosm Biol Aviakosm Med. 1981. PMID: 6111621 Review. Russian. No abstract available.